Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

BACKGROUND: The ICON7 trial previously reported improved progression-free survival in women with ovarian cancer with the addition of bevacizumab to standard chemotherapy, with the greatest effect in patients at high risk of disease progression. We report the final overall survival results of the tri...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Lancet Oncol
मुख्य लेखकों: Oza, Amit M, Cook, Adrian D, Pfisterer, Jacobus, Embleton, Andrew, Ledermann, Jonathan A, Pujade-Lauraine, Eric, Kristensen, Gunnar, Carey, Mark S, Beale, Philip, Cervantes, Andrés, Park-Simon, Tjoung-Won, Rustin, Gordon, Joly, Florence, Mirza, Mansoor R, Plante, Marie, Quinn, Michael, Poveda, Andrés, Jayson, Gordon C, Stark, Dan, Swart, Ann Marie, Farrelly, Laura, Kaplan, Richard, Parmar, Mahesh K B, Perren, Timothy J
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Lancet Pub. Group 2015
विषय:
Articles
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4648090/
https://ncbi.nlm.nih.gov/pubmed/26115797
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(15)00086-8
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन